Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
XmEkCrT7sAkCdQBa